Navigation Links
Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease
Date:4/14/2014

SOUTH SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a publication demonstrating that the company's C1s antibody prevents the destruction of human red blood cells exposed to plasma samples of patients with a type of autoimmune hemolytic anemia (AIHA). The article entitled "TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies" was published on-line in the journal Blood earlier this month. TNT003 is the murine analog of True North's lead humanized monoclonal antibody drug candidate, TNT009, for which the company plans to initiate the first clinical program in 2015.

In ex vivo studies using plasma samples from patients with a type of AIHA known as cold agglutinin disease (CAD), True North demonstrated that red blood cells exposed to patient samples contained high levels of Complement proteins deposited on the cell surface. True North showed that by inhibiting Complement deposition on the red blood cell membrane, TNT003 prevented the red blood cells from being engulfed by macrophages, immune cells responsible for clearing Complement-coated cells and debris from the blood. TNT003 also prevented direct red blood cell lysis driven by a CAD sample that contained unusually high levels of autoantibodies, suggesting that a Complement inhibitor like TNT003 could be efficacious in severe cases of CAD.

"By selectively shutting down the Classical Complement pathway with an antibody, the main drivers of anemia in CAD have been reduced in this preclinical study. Using TNT003 and a large number of 40 patient samples, we were able to deepen the field's understanding of the Complement system's role in this rare disease. The study strengthens the hypothesis that such an approach could be beneficial in this rare patient population," stated Sandip Panicker, PhD, C1s Program Lead and senior author on the journal article in Blood.

TNT003 inhibits C1s, a member of the Complement family of plasma proteins, which, upon activation, trigger a powerful enzymatic cascade that destroys and removes pathogens from the circulation. However, aberrant Complement system activation has been described in numerous autoimmune settings in which antibodies that attack self, known as autoantibodies, play a role in disease pathogenesis. Like other forms of AIHA, CAD is a disorder in which anti-red blood cell antibodies bind to and lead to the destruction of patient red blood cells through Complement system activation.

Dr. Panicker further stated, "As Complement system activity is the only known driver of red blood cell destruction in patients with CAD, the results in the study published in Blood provide compelling evidence for the development of TNT009, the company's lead humanized monoclonal antibody, for the treatment of CAD and potentially other forms of AIHA, for which no approved therapies exist."


'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
845-635-9828
The Yates Network
Source:Eurekalert

Related medicine news :

1. Does the bodys immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?
2. Human stem cells predict efficacy of Alzheimer drugs
3. Osteoporosis drugs compared for side effects, efficacy in Loyola study
4. Despite missing primary efficacy endpoint, ATOMIC-AHF identifies positive trends
5. CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
6. Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis
7. Registry confirms TAVI efficacy and safety in Asian patients
8. Minocycline Enhances the Efficacy of Perispinal Enbrel in Traumatic Brain Injury Treatment as well as Stroke Treatment and Alzheimer’s Treatment
9. CycleBeads Natural Birth Control Method Ranks High in Perfect Use and Typical Use Efficacy According to Most Recent Review of Global Family Planning Reports
10. Study shows long-term efficacy of minimally invasive therapy for patients with Barretts esophagus
11. Muscular Development Store Comments on Efficacy of Protein Blends
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... MLM Insurance Group, a Miami ... southern Florida, is working to support the Take Stock In Children Foundation during ... families. , The Take Stock In Children Foundation (TSC) offers guidance and assistance ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Emotions are sacred, ... Founder of St. Louis-based positive education company Generation Mindful. To help change the mindset ... learn social and emotional skills, she created the Time-In Toolkit, which launched on Kickstarter ...
(Date:8/18/2017)... ... August 18, 2017 , ... Inc. magazine has ranked ... most prestigious ranking of the nation's fastest-growing private companies. This marks the eighth time ... Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue growth ...
(Date:8/18/2017)... ... ... “Three Narrow Roads”: a vivid and provocative look into the narrow path toward ... Sr., is currently the pastor-teacher-visionary at Simply the WORD Church, a global prayer ministry ... program geared towards youth. , King shares, “When I take time to think about ...
(Date:8/18/2017)... ... 2017 , ... “Kingdom Mandate for Kingdom Builders”: a call to walk as ... Builders” is the creation of published author, John F. McGeorge, Jr. Dr. John ... in 1983. He spent three decades training pastors and Christian leaders. He ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy , will ... Cell-Ess® Universal Titer Boost at the 9 th annual ... 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to ... ... Cell-Ess is the ...
(Date:8/15/2017)... FLINT, Mich. , Aug. 15, 2017 ... antidote naloxone to Michigan residents. ... Diplomat,s Flint retail pharmacy, G-3320 ... Naloxone, approved by the Food and Drug Administration, is ... drugs—including extreme drowsiness, slowed breathing, and loss of consciousness. ...
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
Breaking Medicine Technology: